Andean Precious Metals (CVE:APM) Price Target Lowered to C$2.00 at Desjardins

Andean Precious Metals (CVE:APM) had its price objective lowered by equities research analysts at Desjardins from C$2.10 to C$2.00 in a note issued to investors on Thursday,BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. Desjardins’ price objective indicates a potential upside of 55.04% from the stock’s previous close.

Andean Precious Metals Price Performance

Shares of CVE APM traded up C$0.09 during trading on Thursday, hitting C$1.29. 225,691 shares of the company were exchanged, compared to its average volume of 159,585. The company has a market cap of C$135.47 million, a price-to-earnings ratio of 2.55 and a beta of 1.22. Andean Precious Metals has a 1 year low of C$0.57 and a 1 year high of C$2.18. The firm’s fifty day moving average price is C$1.29 and its 200 day moving average price is C$1.36.

Insider Transactions at Andean Precious Metals

In other news, Senior Officer Juan Carlos Sandoval Amare bought 31,300 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was purchased at an average price of C$1.21 per share, with a total value of C$37,860.48. Corporate insiders own 69.37% of the company’s stock.

Andean Precious Metals Company Profile

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.